<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>Sarepta Therapeutics Inc (SRPT): Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

<script>
    (function(_,e,rr,s){_errs=[s];var c=_.onerror;_.onerror=function(){var a=arguments;_errs.push(a);
    c&&c.apply(this,a)};var b=function(){var c=e.createElement(rr),b=e.getElementsByTagName(rr)[0];
    c.src="//beacon.errorception.com/"+s+".js";c.async=!0;b.parentNode.insertBefore(c,b)};
    _.addEventListener?_.addEventListener("load",b,!1):_.attachEvent("onload",b)})
    (window,document,"script","4ffae9d6f05d1da630000008");
</script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Market Currents - Real-time stock market news updates' ,
  'http://seekingalpha.com/currents/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Market Currents - Real-time stock market news updates ;action-uri=http://seekingalpha.com/currents/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure">
<meta name="twitter:description" content="Recently, two companies led the race in developing new drugs to treat Duchenne muscular dystrophy (DMD): eteplirsen from Sarepta Therapeutics (SRPT), and drisapersen from Prosensa (RNA) [partnered with GlaxoSmithKline (">
<meta name='twitter:image' content='http://static1.cdn-seekingalpha.com/images/users_profile/000/789/637/big_pic.png?1383404041'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Sarepta Therapeutics Inc (NASDAQ:SRPT), GlaxoSmithKline plc (ADR) (NYSE:GSK), Prosensa Holding BV (NASDAQ:RNA): Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NASDAQ:SRPT, NYSE:GSK, NASDAQ:RNA" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/1787262" /><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure" />
<meta property="og:description" content="Recently, two companies led the race in developing new drugs to treat Duchenne muscular dystrophy &#40;DMD&#41;: eteplirsen from Sarepta Therapeutics (SRPT), and drisapersen from Prosensa (RNA) [partnered with GlaxoSmithKline" />
<link rel="canonical" href="http://seekingalpha.com/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure" />
<link href="http://static1.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1384704300" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1384704300" media="screen" rel="stylesheet" type="text/css" /><link href="http://static2.cdn-seekingalpha.com/stylesheets/article_packaged.css?1384704301" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var block_script = true;var jhi = 0;</script>
<script type="text/javascript" src="/javascripts/getads.js"></script>


<script type="text/javascript">
  var users_on_site='2,653,138';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script type='text/javascript'>
  if (document.location.protocol !== "https:") {
    var crtg_nid="2227";
    var crtg_cookiename="cto_sa";
    var crtg_varname="crtg_content";
    function crtg_getCookie(c_name){ var i,x,y,ARRCookies=document.cookie.split(";");for(i=0;i<ARRCookies.length;i++){x=ARRCookies[i].substr(0,ARRCookies[i].indexOf("="));y=ARRCookies[i].substr(ARRCookies[i].indexOf("=")+1);x=x.replace(/^\s+|\s+$/g,"");if(x==c_name){return unescape(y);}}return'';}
    var crtg_content = crtg_getCookie(crtg_cookiename);var crtg_rnd=Math.floor(Math.random()*99999999999);
    var crtg_url=location.protocol+'//rtax.criteo.com/delivery/rta/rta.js?netId='+escape(crtg_nid);crtg_url+='&cookieName='+escape(crtg_cookiename);crtg_url+='&rnd='+crtg_rnd;crtg_url+='&varName=' + escape(crtg_varname);
    var crtg_script=document.createElement('script');crtg_script.type='text/javascript';crtg_script.src=crtg_url;crtg_script.async=true;
    if(document.getElementsByTagName("head").length>0)document.getElementsByTagName("head")[0].appendChild(crtg_script);else if(document.getElementsByTagName("body").length>0 && !SA.Utils.Env.isIE7)document.getElementsByTagName("body")[0].appendChild(crtg_script);
  }
</script>
<script src="http://static3.cdn-seekingalpha.com/javascripts/common_packaged.js?1384704261" type="text/javascript"></script>
<script src="http://static.cdn-seekingalpha.com/javascripts/common2_packaged.js?1384704263" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1384704265" type="text/javascript"></script><script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}
</script>

<script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@sectors@';
  var article_sectors_themes = '@short-ideas@us@biotechnology@editors-picks@healthcare@article@';
  var ratings_hash={};
  var ARTICLE_ID = 1787262;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "";
  var author_slug = "steven-breazzano";
  var pticker_for_ads = "srpt";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  var sector_name = "Healthcare";
  var sector_slug = "healthcare";
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

  
</script>
<script>var mone_article_tags = "{gsk,rna,srpt};;;{healthcare};;;{short-ideas,us,biotechnology,editors-picks,investing-ideas};;;{steven-breazzano}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            iframeAd("728x90",'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=728x90;x=x;tile=1;d=investing-ideas;t=short-ideas;axp=1;aid=1787262;d=investing-ideas;d=sectors;t=short-ideas;t=us;t=biotechnology;t=editors-picks;t=healthcare;t=article;z=3;a=steven-breazzano;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/currents/all" sasource="headtabs">Market Currents</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_ideas'>
          <a href="http://seekingalpha.com/dashboard/investing_ideas" sasource="headtabs">Investing Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_income'>
          <a href="http://seekingalpha.com/dashboard/investing_income" sasource="headtabs">Dividends &amp; Income</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='etfs'>
          <a href="http://seekingalpha.com/dashboard/etfs" sasource="headtabs">ETFs</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='macro_view'>
          <a href="http://seekingalpha.com/dashboard/macro_view" sasource="headtabs">Macro View</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">5,147</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">369,757</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>
  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before ">
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure</span>
              </h1>
      <div id="article_info">
        
        <div class="article_info_pos">
          <span>Oct 30 2013, 11:12</span>
          <span id='title_article_comments'></span>
          <span id="page_position"></span>
          <span class="author_name_for_print">by: Steven Breazzano</span>
<span  class='print_hide'>&nbsp;|&nbsp;</span>
            <span class='print_hide'>about:</span> <span  class='print_hide' id='about_primary_stocks'><a href="/symbol/srpt" title='Sarepta Therapeutics, Inc.' sasource='article_primary_about'>SRPT</a></span>,             <span class='print_hide'>includes: </span><span id='about_stocks'><a href="/symbol/gsk" title='GlaxoSmithKline' sasource='article_about'>GSK</a>, <a href="/symbol/rna" title='Prosensa Holding N.V.' sasource='article_about'>RNA</a></span>       	</div>
        <div id="bookmark_top" class="bookmark_container">
  <div id="bookmark_title_top" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_top">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_top" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_top");
</script>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>
    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
          <p>Recently, two companies led the race in developing new drugs to treat Duchenne muscular dystrophy &#40;DMD&#41;: eteplirsen from Sarepta Therapeutics (<a href='http://seekingalpha.com/symbol/srpt' title='Sarepta Therapeutics, Inc.'>SRPT</a>), and drisapersen from Prosensa (<a href='http://seekingalpha.com/symbol/rna' title='Prosensa Holding N.V.'>RNA</a>) [partnered with GlaxoSmithKline (<a href='http://seekingalpha.com/symbol/gsk' title='GlaxoSmithKline'>GSK</a>)]. These novel, late-stage drug candidates from both companies feature the same mechanism of action and target specific forms of DMD. Recently, and unfortunately for investors and patients, Prosensa / GSK's drisapersen <a href="http://www.gsk.com/media/press-releases/2013/gsk-and-prosensa-announce-primary-endpoint-not-met-in-phase-iii-.html" rel="nofollow">failed</a> to meet its primary endpoint (p = 0.41) and all secondary endpoints in its pivotal phase 3 clinical trial. The trial was double-blind, placebo controlled, and robust, enrolling 186 patients in 47 trial sites across 20 countries. Prosensa even possessed the coveted &quot;Breakthrough Designation&quot; from FDA, highlighting its preliminary efficacy and potential. In the accompanying conference call, management did not provide any additional analyses supporting efficacy, or offer any credible hypotheses for the lack of perceived clinical benefit. In short, it was a total failure.</p><p>However, Sarepta Therapeutics stock, reacted positively on the news, increasing almost 18% that day on heavy volume and later peaking near $56/share (although, the stock is now only up 14% since the announcement). One can only speculate, but the increase is presumably based on the notion that the major competitor has now been eliminated. But what does the Prosensa failure really mean for investors? We have done a thorough scientific analysis, which is described below.</p><p>Our objective analysis of drisapersen's failure and comparison with Sarepta's eteplirsen points to significantly increased clinical risk for Sarepta's proposed phase 3 confirmatory trials as well as plans for accelerated approval in 2014. We do not think the largely retail investor base, which is responsible for Sarepta's high valuation, has an understanding of these risks.</p><p><strong>Duchenne muscular dystrophy</strong> is an insidious and severely debilitating childhood neuromuscular <a href="http://en.wikipedia.org/wiki/Duchenne_muscular_dystrophy" rel="nofollow">disease</a> that affects approximately 1 in 3,500-5,000 live male births. This rare disease is caused by mutations (i.e. deletions, duplications, point mutations) in the dystrophin gene, ultimately resulting in the absence or defective versions of the critical dystrophin protein. Clinically, patients suffer from progressive loss of muscle strength, often rendering them wheelchair-bound before the age of 12. Respiratory and cardiac muscle can also be affected by the disease, and most patients ultimately die in early adulthood due to respiratory and cardiac failure. However, less severe forms of muscular dystrophy, including mild Becker muscular dystrophy result in semi functional dystrophin (e.g. truncated or slightly altered dystrophin) and less severe muscle loss. These patients generally have longer life expectancies and lose ambulation later in life.</p><p><strong>Eteplirsen and Drisapersen Mechanism of Action</strong> - The dystrophin gene is the largest gene in the body, consisting of 79 exons. In DMD, the open-reading frame of certain key exons is disrupted, resulting in a non-functional dystrophin protein and the severe symptoms and forms of DMD. While the chemistry backbone underlying drisapersen and eteplirsen differ, (explored later in the article), the mechanism of action is similar. These drugs both seek to skip exons (in this case, exon 51) and thereby correct the reading frame to enable the production of a novel, functional dystrophin protein. This novel, truncated dystrophin is designed to be similar to that seen in the milder Becker muscular dystrophy patients.</p><p>Currently, to measure efficacy in DMD, both SRPT and RNA utilize the 6 minute walk test (6MWT). This clinical endpoint is exactly what it sounds like: how far can a patient walk in 6 minutes. The idea is simple, for patients who still are able to walk; this ability will diminish over time until patients become wheel chair bound. Thus, measuring the stabilization / lack of regression in walking ability via the 6MWT is clinically meaningful. There is little doubt that FDA is moving towards straightforward, all encompassing, and clinically meaningful endpoints such as this, but it also raises significant challenges. This endpoint is extremely variable, as we'll see below. As a result, this makes statistical analysis, powering, and interpretation of studies that much more difficult. Furthermore, this variability makes larger clinical trials a necessity. Before looking into the dystrophin hypothesis, a look at the 6MWT results provides insight into the challenges facing SRPT and other developers of novel drugs for DMD.</p><p><strong>Prosensa's Clinical Trials</strong> - Drisapersen has been evaluated in multiple small trials and the previously mentioned, pivotal trial. The smaller trials are listed below:</p><ol><li>Phase 1/2 study with 12 patients treated with 0.5, 2, 4, and 6 mg/kg for 5 weeks. These patients were then treated with 6 mg/kg for 141 more weeks.</li><li>Demand-2 study with 53 patients treated with either 1) 6 mg/kg weekly, 2) 6 mg/kg intermittently, or 3) placebo. Patients were dosed for 48 weeks.</li><li>Demand-5 study with 51 patients treated with either 3 mg/kg or 6 mg/kg weekly for 48 weeks.</li></ol><p>In summary, the smaller phase 1/2 dose escalation study portion demonstrated stabilization in the long-term extension study where the patients received 6 mg/kg for 141 more weeks, stabilizing walking in 8 out of 10 patients, shown below:</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId10.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId10_thumb.jpg" /></a></p><p>In addition, Demand 2 and Demand 5 also demonstrated stabilization / improvement in walking. In Demand 2, a placebo controlled trial (graph shown below), improvement was seen at 49 weeks in the 6 mg/kg continuous +11.2 m, 6 mg/kg intermittent +2.4, but a decrease in the placebo arm of -24.7 m. However, based on articles from thestreet.com, it appears that even though the trial was placebo controlled, patients and their families deduced if they were on the drug due to the painful nature of the injection. This may explain the &quot;bump&quot; seen initially with treatment and accounts for the improvement in walking relative to placebo. This hypothesis further underscores the variable nature of the 6MWT and the challenges associated with interpretation of data in these small trials.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId11.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId11_thumb.jpg" /></a></p><p>In Demand 5, improvement was seen again in the 6 mk/kg dose with a decrease in 3 mg/kg and placebo trials. Based on these promising results, a pivotal trial was conducted. As previously mentioned, 186 boys were treated 6 mg/kg weekly for 48 weeks vs. placebo. Overall, patients treated with drisapersen declined 42.3 m, vs. 52.7 m for placebo. The graph below shows the results of the multi-center pivotal phase 3 trial. (Source: Adam Feuerstein, TheStreet.com)</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId12.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId12_thumb.jpg" /></a></p><p>So what happened and what does this mean?</p><p>There are a number of potential factors at work. First, it demonstrates that walking stabilization over long time periods is indeed possible, and even likely in smaller, open-label trials with a highly variable clinical endpoint. More broadly, many factors may be at work that are not necessarily specific to DMD. For example, doctors may select only the most promising patients, and parents who are most motivated may enroll their children in these studies. The 6MWT is a highly variable endpoint. In addition, there is likely strong placebo effect, especially in open label trials. These factors can easily lead to a false signal of efficacy. This is undoubtedly the case for drisapersen, where the promising results in small numbers of patients did not translate to the results of a larger study.</p><p><strong>Sarepta's eteplirsen</strong> - Taking a look now at SRPT's eteplirsen clinical trials results, a similar pattern emerges. While the trial designs are slightly different (ages varied slightly), many of the same characteristics are seen, facilitating the comparison. In particular, SRPT's primary efficacy trials, study 201 and its extension study 202, enrolled 12 patients, identical to the extension study by Prosensa which tested the phase 3 dose of 6 mg/kg. Eteplirsen was given in 30 mg/kg and 50 mg/kg doses, and compared with a placebo arm. After 24 weeks, the placebo arm was randomized and patients (2 each) were either given 30 mg/kg or 50 mg/kg. Therefore, after 24 weeks all patients are receiving drug, although at 2 different doses.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId13.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId13_thumb.jpg" /></a></p><p>In these trials, eteplirsen demonstrated improvement in walking. SRPT removed two patients from the modified intent to treat analysis due to rapid loss of ambulation early on (two patients in Prosensa's trial also lost ambulation). It is easy to get bogged down in the statistical details and the validity of the various tests used, but this misses the bigger picture. Looking at the aggregated data below from a recent SRPT poster, stabilization of walking was seen. Overall, the graphs do not look far different than the ones above for Prosensa. In addition, SRPT's trial was conducted at a single center and the extension portion was open label. Hence, we have the same set-up for SRPT as we had for RNA.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId14.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId14_thumb.jpg" /></a></p><p><strong>Dystrophin levels</strong> - In addition to the 6MWT, the clinical endpoint, dystrophin levels were also measured by muscle biopsy during these trials, primarily to validate the biological hypothesis and mechanism of action as well as to support regulatory approval. On the surface, the biological hypothesis is clean and logical; restoring semi-functional dystrophin production will restore, or at least, prevent further deterioration of muscle weakness. While Prosensa and Sarepta both measured dystrophin levels (they look at % of fibers expressing dystrophin as well as intensity per fiber), there are differences in methodology and timing of biopsies. SRPT calibrates their results to baseline biopsies, while Prosensa does not explicitly do so for all patients. However, results can still be compared on a qualitative basis. It is well documented by both Prosensa and SRPT that patients have &quot;revertant&quot; fibers that express some dystrophin, and any analysis must take this into account. Overall, it appears that SRPT's eteplirsen acts more slowly, given the 0.8% increase in dystrophin positive fibers at 12 weeks at the 50 mg/kg dose and 22.4% at 24 weeks at the 30 mg/kg dose vs. Prosensa's drisapersen which appears to work much more quickly; large increases in overall dystrophin positive fibers (57%-75% in 7 weeks and earlier compared to baseline levels of 7% and lower signal intensity). Therefore, it is unlikely that eteplirsen will succeed based on this dystrophin data.</p><p>In addition, in study 201, there was a discrepancy in dystrophin production and its correlation with the 6MWT. Dystrophin production was measured for the 50 mg/kg dose and demonstrated a 0.8% increase in dystrophin positive fibers at 12 weeks (not stat. significant), but demonstrated stat. significance for the 50 mg/kg dose on the 6MWT combined with the significant dystrophin production at the 30 mg/kg (22.5% at 24 weeks) but insignificant benefit on the 6MWT calls into question the biological hypothesis of dystrophin production and its associated clinical benefit. Also, the lack of a robust dose response in the 30 and 50 mg/kg arms calls for a larger study to confirm these results (the 30 mg/kg results in higher dystrophin positive fibers than the 50 mg/kg, and the opposite is true in the delayed treatment arm).</p><p>Key Publications: <a href="http://onlinelibrary.wiley.com/doi/10.1002/ana.23982/abstract" rel="nofollow">SRPT Annals of Neurology</a> 2013, <a href="http://www.ncbi.nlm.nih.gov/pubmed/21784508" rel="nofollow">SRPT (AVI Biopharma) Lancet 2011</a>, <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1011367" rel="nofollow">RNA NEJM 2011</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/18160687" rel="nofollow">RNA NEJM 2007</a>.</p><p><strong>FDA accelerated approval</strong> - As investors know, accelerated approval allows a drug to be approved based on a surrogate or an intermediate clinical endpoint. A surrogate endpoint used for accelerated approval is a marker - a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. SRPT has held meetings with FDA to explore the potential for accelerated approval, and based on these meetings and conversations with FDA, SRPT believes and has disclosed that the agency is willing to consider approval of eteplirsen based on dystrophin levels as a surrogate endpoint. Accelerated approval allows the drug to enter the market sooner, providing the sponsor runs confirmatory trials to measure the ultimate clinical benefit. In this case, the idea is that SRPT will then presumably confirm that the increased dystrophin levels lead to improved clinical outcomes and significant stabilization / improvement of walking long term.</p><p>However, this raises two key questions for the FDA reviewers (and investors):</p><ol><li>Is increased dystrophin predictive of clinical benefit?</li><li>How much dystrophin is required for a clinical benefit?</li></ol><p>The previous analysis of Prosensa's dystrophin data and comparison with Sarepta's data (although not all of it is available, particularly for the 50 mg/kg dose) suggest that at the current levels, the answer so far to 1) is no, dystrophin levels are not predictive of clinical benefit. Would higher doses over much longer time frame make a difference? Potentially, but not based on the evidence so far. Based on the large amount of data that has been generated to date, which has not been thoroughly analyzed by investors, we think the default position should be that dystrophin levels are not predictive of clinical benefit.</p><p>A <a href="http://www.ncbi.nlm.nih.gov/pubmed/8411069" rel="nofollow">literature</a> report characterizing different cohorts based on severity of disease provides clues to help answer question 2).</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId20.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/789637_13831346945304_rId20_thumb.jpg" /></a></p><p>In rough agreement with Prosensa and Sarepta's publications, the most severe DMD patients have clearly very little functional dystrophin, ~5-7%. In addition, in the next clinical cohort, it appears 12-15% or so abundance of dystrophin affords a more mild form of the disease, and results in a less rapid disease progression. Given that the number of dystrophin positive fibers in SRPT's trials is lower than Prosensa's, it is unlikely that eteplirsen will succeed. However, for the sake of argument, a simple proxy may be used for total dystrophin levels. Multiplying % increased dystrophin fibers by the intensity per fiber can yield a crude estimation of total dystrophin production. From SRPT's recent poster, approximately ~50% of fibers were dystrophin positive at 48 weeks in the desired 30 mg/kg dose, and utilizing an aggressive assumption that says intensity increased by 15% (up to 2.5x better than the 4% change reported at 20 mg/kg), this implies that total dystrophin may be increased by 7.5% over the course of 1 year or less (remember, it appears to work slower). Keep in mind that this improved clinical cohort has had extra dystrophin production from birth, not just 1 year!</p><p>There is no question FDA is in a difficult position. The clinical course of DMD is well-known, and eteplirsen is a novel therapy with the promise to make a significant impact on patients' lives. It also looks like eteplirsen has a more benign and cleaner safety profile relative to drisapersen, bolstering the case for accelerated approval. However, the use of dystrophin as a surrogate endpoint and its correlation with the 6MWT is not based on robust evidence. Furthermore, there is no clear evidence that eteplirsen produces more functional dystrophin than drisapersen, and in light of the drisapersen failure, there is extremely limited evidence to support that increases in the levels of dystrophin seen by RNA and SRPT are indicative of clinical benefit. In addition, the lack of a strong dose response for eteplirsen and lack of strong correlation with a clinical outcome casts doubt over the trial results. As such, it is highly unlikely that FDA will grant accelerated approval to SRPT based on the small, single center trial. It is likely that FDA will require them to run a phase 3 trial prior to approval, which has a significant chance of failing to demonstrate efficacy, just as drisapersen did. We strongly believe, given the large amount of data now available, that the default assumption for investors should be that FDA will not grant accelerated approval and eteplisren will likely fail a large randomized study just as drisapersen did. We further believe that SRPT's proposed open label confirmatory trial with a &quot;placebo&quot; arm of patients with non-amenable mutations will be rejected by FDA.</p><p><strong>Additional Considerations</strong> - Sarepta bulls point to several key factors that improve the chances of success for SPRT. These arguments are focused on two main points: patient age and dosage.</p><p><strong>Age</strong> - The average age of eteplirsen patients in its phase 1/2 trial was approximately 9 years. In the early trials of drisapersen, the average age was 7-8 years. The argument here is that comparison is not valid, and trials enrolling patients of different health and ability cannot be compared. While exact disease progression by age is unknown, what is potentially true is that individual patient variability is likely the greatest source of variation in these small trials. If anything, it may be surmised that earlier intervention and younger patients may favor drisapersen.</p><p><strong>Dosage</strong> - Based on recent calls by SRPT, if approved, the likely dosage of eteplirsen will be 30 mg/kg, approximately 5x higher than drisapersen's phase 3 trial dosage of 6 mg/kg. However, we have some clues to their PK and PD properties. Eteplirsen's half-life is approximately 1.6-3.6 hours, whereas drisapersen's mean terminal half-life is 29 days. On an area under the curve basis, this likely leads to far higher effective dosages of drisapersen relative to eteplirsen. Now, this is not the only factor to consider, as PK/PD properties are dependent on many elements including binding affinity, rate of degradation, etc. However, there is nothing to truly suggest convincingly that Sarepta will succeed where Prosensa has failed. Although, there is some evidence to suggest morpholinos (Sarepta's technology) are more selective and have less off-target effects than Prosensa's anti-sense compound.</p><p><strong>Financials and Valuation</strong> - With the recent sell-off bringing the stock off its 52 week highs, SRPT's $42 share price combined with 33.5 M shares outstanding leads to a still staggering $1.4 B market capitalization. Clearly, with only 12 patients' worth of data, this lofty valuation factors in success not only for the current candidate, but also follow-on exon-skipping drugs targeting the additional DMD mutations. Given the challenges outlined facing SRPT, this valuation clearly overestimates the probability of clinical and regulatory success.</p><p>To management's credit, they have taken advantage of the meteoric stock price increase (and potentially overvalued stock) to raise a significant amount of equity capital. As of June 30, 2013, Sarepta had cash and cash equivalents of $164 M, but has raised nearly $38 M more with an at-the-market (ATM) equity financing (current as of August 7, 2013). SRPT will not need additional capital in the near term, although it is likely they will continue to tap the ATM for additional capital if the stock price remains high.</p><p><strong>Conclusions</strong> - While new potential treatment options in DMD are a positive for patients, investor enthusiasm must objectively access asset value in light of the stock price and the discount associated with clinical and regulatory risk. Prosensa's failure should not have lead to an increase in Sarepta's share price, given the similarity in the underlying unproven technology and the misleading nature of small studies utilizing the 6MWT endpoint. This space lacks the success of a large, randomized controlled trial probably because these products are not effective. The dystrophin data and lack of correlating efficacy point to significant clinical and regulatory risk. As a result, it is unlikely that FDA will accept accelerated approval. Even more unlikely is that a large, randomized controlled clinical trial shows a statistically significant benefit. These risks should be reflected by a discounted valuation. Sarepta Therapeutics' $42 share price and $1.4 B market capitalization significantly overestimate the true value of the stock given the risks, and this fundamental mispricing is likely to be corrected within the next 12 months as events unfold.</p>
            <div id="article_source">Source: <a href="/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure?source=cc">Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I have no positions in any stocks mentioned, but may initiate a short position in <a href='http://seekingalpha.com/symbol/srpt' title='Sarepta Therapeutics, Inc.'>SRPT</a> over the next 72 hours. <span id="additional_business_disclosure" style="display:none">I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.</span> <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <script>SA.Pages.Article.handleDisclosures();</script>
        <div id="content_follow_up" class="underbar">
          <div id="follow_wrap">
              <div id="article_rta_bottom_container">
                <div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">5,147</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>

<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      369,757
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="techpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id="techpromo_button" onclick="SA.Pages.Article.sendTechPromoMail()"></div>
</div>

<div id="ipadpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml90'>The #1 Portfolio App is Now on iPad!</div>
  <div id='sms_promo_line2' class='sms_line2 ml5 fwb mt10'>Get instant notifications & never miss a critical update on your stocks!</div>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt30"><div id="ipadpromo_button"></div></a>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt20"><div id="get_the_app"></div></a>
  <div id="ipadpromo_stars" class="fl mt15"></div>
</div>

<div id="store_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml25'>Which Seeking Alpha App is best for you?</div>
  <div class="mt15">
    <div class="ml25">
      <div class="fl"><input id="app_portfolio" type="checkbox"/></div>
      <div class="fl fwb ml10">Seeking Alpha Portfolio</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_tech" type="checkbox"/></div>
      <div class="fl fwb ml10">Tech Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_etf" type="checkbox"/></div>
      <div class="fl fwb ml10">ETF investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_energy" type="checkbox"/></div>
      <div class="fl fwb ml10">Energy Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="light-gray mt20 ml25">Email me a link to open from my phone:</div>
    <div class="ml25 mt5">
      <input id="email_to_download" type="text" style="width: 300px" class="fl" emailautofill="on" title="Email address" empty="Email address"/>
      <div class="bs-btn fl btn-primary ml10 btn-mini fwb" style="width: 70px;" onclick="SA.Pages.Article.sendLinkDownload()">Continue</div>
      <div class="cb"></div>
      <div class="red fs11" id="email_td_error"></div>
    </div>
  </div>
</div>

<div id="web_video_container" style="display:none" class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/LFNN6lhLtkk" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20" style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="ipad_video_container" style="display:none"  class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/zEnMPGkjOnI" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20"  style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>


              </div>
              <div id="article_rta_middle_container" style="display:none">
                <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         5,147
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">369,757</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

              </div>
     		    <div id="article_tags" style="display:none">
              <div itemprop="articleSection" class="tagged_with">
                <span class="tagged_with_label">Tagged: </span><a href='/dashboard/investing_ideas' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/short-ideas' sasource='article_navigation'>Short Ideas</a>, <a href='/analysis/sectors/healthcare' sasource='article_navigation'>Healthcare</a>, <a href='/articles?filters=biotechnology' sasource='article_navigation'>Biotechnology</a>, <a href='/analysis/all/editors-picks' sasource='article_navigation'>Editors&#x27; Picks</a>
              </div>
	          </div>
            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this article with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',1787262,'http://seekingalpha.com/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of P... http://seekingalpha.com/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure?source=tweet $GSK $RNA $SRPT" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure?source=share" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/1787262-sarepta-therapeutics-underappreciated-clinical-and-regulatory-risk-following-analysis-of-prosensa-failure?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <!-- Plusone  -->
      <span class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '1787262'
        }
      });
    });
  </script>
  </li>
</ul>            </div>
            <div class="bookmark_bottom_wrapper"><div id="bookmark_bottom" class="bookmark_container">
  <div id="bookmark_title_bottom" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_bottom">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_bottom" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_bottom");
</script></div>
	          <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="more_by_auth" class="more_by_auth"></div>
            <div id="more_by_ticker" class="article_bottom_units"></div>
            <div id="temporary_place_holder" class="mt10"></div>
            <div class="cleaner"></div>
          </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
      <div id="secondary_ads" class="no_big_gaps_secondary_ads" style="float:right;">
        <div id="author_avatar">
    <div class="follow_sidebar">
      <script>var author_info_popup_timeout;</script>
<div id="author_info"> 
  <div class="author_page_tools" id="author_image_header">
    <div class="author_info_wrap">
      <a href="/author/steven-breazzano" class='this_is_a_author_pic' sasource="about_lpic"><img class="this_is_a_author_pic_img" align="center" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/789/637/big_pic.png?1383404041" width="115" height="115" alt="Steven Breazzano picture" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();" /></a>
 <div id="goto_edit_picture" class="goto_edit_picture" style='display:none'><span onclick="return goto_update_picture();" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();"></span></div>
        <div id="article_author_info" style="display:none;" onmouseover="clearAuthorInfoPopupTimeout();" onmouseout="HideAuthorInfo();">
          <div>
            <div class="followup_contributor_info">
  <div class="followup_contributor_info_title">
    <span>About the author: </span>
    <a href="/author/steven-breazzano" sasource="about_name">Steven Breazzano</a>
  </div>

  <div class="followup_contributor_info_on_author">
    <div class="followup_contributor_info_pic_cont">
      <div class="pic_cont">
        <div class="pic_contributor">
          <div class="the_pic">
              <a href="/author/steven-breazzano" sasource="about_pic"><img align="center" width="54" height="54" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/789/637/big_pic.png?1383404041" alt="Steven Breazzano picture"/></a>
          </div>
        </div>
      </div>
    </div>
    <div class="followup_contributor_info_text">
      Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research. Steven is... <a href='/author/steven-breazzano' sasource='about_more'>More</a>
    </div>
    <div class="cleaner"></div>
	</div>
  <div class="followup_contributor_info_bottom_cnt">
    
    <div class="left_cnt">
      
    </div>
  </div>

  <div class="cleaner"></div>
</div>
<div class="followup_contributor_info_on_author_bottom"></div>

          </div>
        </div>
    </div>
    <a href="/author/steven-breazzano" itemprop="author" class="author_info_name" sasource="about_lname">Steven Breazzano</a>
    <div class="cleaner"></div>
    <div class="author_info_nav_border">
      <div class="author_info_nav">
        <ul class="the_author_info_nav">
          <li><a href='/author/steven-breazzano/articles'>Articles <span>(49)</span></a></li>
                                    <li>
                   <a href='/author/steven-breazzano/comments'>Comments <span>(330)</span></a>
                 </li>              <script>if (/stats viewer/.test(readCookie("user_perm"))) document.write("<li><a href='/account/authorboard/earnings?for_user_id=789637'>Earnings</a></li>");</script>
          <li><a href='/author/steven-breazzano'>Profile</a></li>        </ul>
      </div>
    </div>
    <div class="cleaner"></div>
    <div class="user_followers_following">
      <div class="user_followers">
        <a href="/author/steven-breazzano/followers">
          <span id="followers" class="number followers_number_789637 followers_number_steven-breazzano">353</span>
          <span class="text">Followers</span>
        </a>
      </div>
      <div class="user_followers">
        <a href="/author/steven-breazzano/following">
          <span id="followings" class="number">28</span>
          <span class="text">Following</span>
        </a>
      </div>
    </div>

    <div id="follow_this_user" class="follow_this_user"></div>
    <script>Follow.author_sidebar__follow_button_initiator('steven-breazzano')</script>
    <span class='author_info_send_message' onclick='Messaging.sendMessage("a2r5x5az", "Article Author ID Card Upper")'>Send Message</span>
    <div class="cleaner"></div>
  </div>
  <div class="follow_popup_wrapper">
      <div class="green_pop_wrapper" id="stop_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('stop_follow').style.display='none'"></span><p><span id="stop_follow_message"></span> Steven Breazzano</p><span class="stop_following" onclick="Follow.ajax_stop_follow_this_author(this, 'steven-breazzano')">Stop Following</span></div></div><div class="green_pop_wrapper" id="no_longer_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('no_longer_follow').style.display='none'"></span><p><span id="no_longer_message"></span> Steven Breazzano</p></div></div>  </div>
</div>
  <script>SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),17162)})</script>

    </div>
    <div class="cleaner"></div>
    
    </div>
          <div class="stickyad_wrapper">
            <div class="item banner160x600" id="fixed_banner160x600">
            </div>
          </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;axp=1;aid=1787262;d=investing-ideas;d=sectors;t=short-ideas;t=us;t=biotechnology;t=editors-picks;t=healthcare;t=article;z=3;a=steven-breazzano;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div class="item banner300x600">
      <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=short-ideas;axp=1;aid=1787262;d=investing-ideas;d=sectors;t=short-ideas;t=us;t=biotechnology;t=editors-picks;t=healthcare;t=article;z=3;a=steven-breazzano;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
    </div>
      <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
    <script type="text/javascript">
      ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
    </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "SRPT";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


    <div id="register_login_snippet"></div>
    
    <div id="side_customize" class="side_customize"></div>
    <div id="portfolio_form_box"></div>

      <div id="article_sidebar" class="article_sidebar">
        <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
      </div>

    <div id="articles_on_my_portfolio"></div>
      <div class="cleaner"></div>
      <div class="stickyad_wrapper">
        <div class="item banner300x250" id="article_dart_sticky"></div>
      </div>
       
  </div>

  <script>
      SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;axp=1;aid=1787262;d=investing-ideas;d=sectors;t=short-ideas;t=us;t=biotechnology;t=editors-picks;t=healthcare;t=article;z=3;a=steven-breazzano;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>

<script src="http://static1.cdn-seekingalpha.com/javascripts/portfolio_form_popup_box_packaged.js?1384704274" type="text/javascript"></script>  
   </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/12b26" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/page/sa-mobile-apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2013 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
      
    </div>
   
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    Event.observe(window, 'scroll', check_positions);

    NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
    SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=160x600;x=x;tile=3;d=investing-ideas;t=short-ideas;axp=1;aid=1787262;d=investing-ideas;d=sectors;t=short-ideas;t=us;t=biotechnology;t=editors-picks;t=healthcare;t=article;z=3;a=steven-breazzano;cnt=7;cnt=20;pr=srpt;s=gsk;s=rna;s=srpt;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>
<script>
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})}
    SA.Pages.Article.primary = "srpt";
    SA.Pages.Article.init();
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }
      
    if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);}
    var pagination_version = ABTest.identity%10;

    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      SA.Pages.Article.btb();

  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){ 
      SA.Pages.Article.articlePromo({"allSlugs":["gsk","rna","srpt"],"primarySlug":"srpt","dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
</script>
      <script src="http://static2.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1384704275" type="text/javascript"></script>
<link href="http://static1.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1384704301" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static2.cdn-seekingalpha.com/javascripts/sa.js?1384704249");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static3.cdn-seekingalpha.com/javascripts/tops.js?1384703941");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css')});
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static.cdn-seekingalpha.com/javascripts/footer_packaged.js?1384704273" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"}
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?144';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?148';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>

<script type="text/javascript">if (typeof NREUMQ !== "undefined") { if (!NREUMQ.f) { NREUMQ.f=function() {
NREUMQ.push(["load",new Date().getTime()]);
var e=document.createElement("script");
e.type="text/javascript";
e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" +
  "js-agent.newrelic.com/nr-100.js";
document.body.appendChild(e);
if(NREUMQ.a)NREUMQ.a();
};
NREUMQ.a=window.onload;window.onload=NREUMQ.f;
};
NREUMQ.push(["nrfj","beacon-5.newrelic.com","c0370b1d43","334927,334928","cldeEUAJWgldEBsASkVRUwlXFRkWUA1D",0,56,new Date().getTime(),"","","","",""]);}</script>
    <div class="cleaner"></div>
  </body>
</html>
